1
|
Matsuoka O, Tsuzuki D, Suzuki K, Tanaka T, Takagi Y, Oster P. Immunogenicity and Safety of a Two-Dose Series of a Meningococcal (Groups A, C, W, and Y) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Men-ACWY-D) in Healthy Japanese Adults. Jpn J Infect Dis 2020; 74:193-199. [PMID: 33132297 DOI: 10.7883/yoken.jjid.2020.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine (Men-ACWY-D) has been licensed for use in Japan since 2014. An earlier registration study demonstrated the immunogenicity of a single dose in Japanese adults, wherein the immunogenicity against serogroup C was the lowest. The determination of the potential to increase the serogroup C response with a second dose was, therefore, of interest. This study (NCT02591290) evaluated the safety and immunogenicity of two doses administered 8 weeks apart to 60 healthy Japanese adults aged 20-55 years. Blood samples were collected at 28-35 days after vaccination. Immunogenicity endpoints included seroprotection and seroconversion rates. Safety assessments included systemic adverse events (AEs), non-serious AEs, and serious AEs. Fifty-eight participants (96.7%) completed the study. The seroprotection rates for serogroups A, C, W, and Y before vaccination were 76.8%, 26.8%, 26.8%, and 50.0%, respectively, increasing to 100%, 83.9%, 91.1%, and 96.4% and 100%, 92.9%, 94.6%, and 94.6%, respectively, after two doses. The seroconversion rates for the four serogroups were 100%, 93.8%, 97.1%, and 94.1%, respectively, after the first dose, and 100%, 96.9%, 100%, and 100%, respectively, after the second. The increase between the doses was insignificant, and there were no safety concerns. The two-dose series was well tolerated; however, the clinical benefits of a second dose within 8 weeks seemed to be low.
Collapse
|
2
|
Ferlito C, Biselli R, Cattaruzza MS, Teloni R, Mariotti S, Tomao E, Salerno G, Peragallo MS, Lulli P, Caporuscio S, Autore A, Bizzarro G, Germano V, Biondo MI, Picchianti Diamanti A, Salemi S, Nisini R, D'Amelio R. Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults. Clin Exp Immunol 2018; 194:361-370. [PMID: 30099753 DOI: 10.1111/cei.13202] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/06/2018] [Indexed: 12/19/2022] Open
Abstract
Meningococcal polysaccharide (Men-Ps) vaccine immunogenicity following either primary immunization or revaccination in adults was evaluated. The study population consisted of subjects who have received tetravalent Men-Ps vaccine once (group 1) or at least twice, with a 2-6 dose range (group 2). Human leucocyte antigen (HLA)-typing was performed by polymerase chain reaction and specific immunoglobulin (Ig)G was measured by enzyme-linked immunosorbent assay. Nine months post-immunization, the percentages of individuals with levels of anti-Men-Ps IgG ≥ 2 µg/ml were comparable in both groups, with the exception of anti-Men-PsW135 IgG, which were significantly higher in group 2. The percentage of subjects doubling IgG levels at 9 months was significantly higher in group 1. The high baseline anti-Men-Ps antibody levels negatively influenced the response to revaccination, suggesting a feedback control of specific IgG. The calculated durability of anti-Men-Ps IgG was 2·5-4·5 years, depending on the Men-Ps, following a single vaccine dose. No interference by other vaccinations nor HLA alleles association with immune response were observed. This study confirms that Men-Ps vaccine in adults is immunogenic, even when administered repeatedly, and underlines the vaccine suitability for large-scale adult immunization programmes that the higher costs of conjugate vaccines may limit in developing countries.
Collapse
Affiliation(s)
- C Ferlito
- Sapienza Università di Roma, Dipartimento di Medicina Clinica e Molecolare, Azienda Ospedaliera Universitaria S. Andrea, Rome, Italy
| | - R Biselli
- Aeronautica Militare Italiana, Comando Logistico, Servizio Sanitario, Rome, Italy
| | - M S Cattaruzza
- Sapienza Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Rome, Italy
| | - R Teloni
- Istituto Superiore di Sanità, Dipartimento Malattie Infettive, Rome, Italy
| | - S Mariotti
- Istituto Superiore di Sanità, Dipartimento Malattie Infettive, Rome, Italy
| | - E Tomao
- Aeronautica Militare Italiana, Corpo Sanitario, Rome, Italy
| | - G Salerno
- Sapienza Università di Roma, Dipartimento di Medicina Clinica e Molecolare, Azienda Ospedaliera Universitaria S. Andrea, Rome, Italy
| | - M S Peragallo
- Esercito Italiano, Centro Studi e Ricerche di Sanità e Veterinaria, Rome, Italy
| | - P Lulli
- Sapienza Università di Roma, Dipartimento di Medicina Clinica e Molecolare, Azienda Ospedaliera Universitaria S. Andrea, Rome, Italy
| | - S Caporuscio
- Sapienza Università di Roma, Dipartimento di Medicina Clinica e Molecolare, Azienda Ospedaliera Universitaria S. Andrea, Rome, Italy
| | - A Autore
- Aeronautica Militare, Comando Logistico, Centro Sperimentale di Volo, Aeroporto Pratica di Mare, Rome, Italy
| | - G Bizzarro
- Aeronautica Militare, Comando Logistico, Centro Sperimentale di Volo, Aeroporto Pratica di Mare, Rome, Italy
| | - V Germano
- Sapienza Università di Roma, Dipartimento di Medicina Clinica e Molecolare, Azienda Ospedaliera Universitaria S. Andrea, Rome, Italy
| | - M I Biondo
- Sapienza Università di Roma, Dipartimento di Medicina Clinica e Molecolare, Azienda Ospedaliera Universitaria S. Andrea, Rome, Italy
| | - A Picchianti Diamanti
- Sapienza Università di Roma, Dipartimento di Medicina Clinica e Molecolare, Azienda Ospedaliera Universitaria S. Andrea, Rome, Italy
| | - S Salemi
- Sapienza Università di Roma, Dipartimento di Medicina Clinica e Molecolare, Azienda Ospedaliera Universitaria S. Andrea, Rome, Italy
| | - R Nisini
- Istituto Superiore di Sanità, Dipartimento Malattie Infettive, Rome, Italy
| | - R D'Amelio
- Sapienza Università di Roma, Dipartimento di Medicina Clinica e Molecolare, Azienda Ospedaliera Universitaria S. Andrea, Rome, Italy
| |
Collapse
|
3
|
Millar BC, Moore PJA, Moore JE. Meningococcal disease: has the battle been won? J ROY ARMY MED CORPS 2016; 163:235-241. [PMID: 28039342 DOI: 10.1136/jramc-2016-000695] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Revised: 10/25/2016] [Accepted: 10/27/2016] [Indexed: 11/03/2022]
Abstract
Meningococcal disease is a worldwide life-threatening infection associated in many cases with debilitating long-term sequelae, both within the military and civilian populations. Military recruits are at a higher risk of acquiring this infection due to numerous factors, such as young recruits in the age group 18-25 years, high carriage rates of meningococci, communal and crowed living quarters and global deployment or training in regions with different meningococcal serogroup epidemiology. Although these increased risk factors among young recruits remain, the increased incidence of disease is now historic. Numerous outbreaks have been reported among military personnel, however although the incidence of the disease continues to decrease, there are still sporadic cases. The non-specific symptoms, sudden onset and rapid progression of the infection results in a limited time frame to both diagnose and successfully treat the patient. Many developments have been made in relation to the microbiological diagnosis of the disease, particularly in the era of molecular diagnostics, which have the potential to diagnose the infection more quickly. Developments in vaccinology, and in particular with relation to biotechnology and reverse vaccinology, have led to the availability of new meningococcal vaccines, further enabling disease prevention. This paper outlines the history of meningococcal disease in relation to the military and highlights the new developments in both diagnostics and vaccination, which have the potential to diagnose, treat and control meningococcal disease in a more efficient manner.
Collapse
Affiliation(s)
- Beverley C Millar
- Northern Ireland Public Health Laboratory, Department of Bacteriology, Belfast City Hospital, Belfast, UK
| | - P J A Moore
- School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
| | - J E Moore
- Northern Ireland Public Health Laboratory, Department of Bacteriology, Belfast City Hospital, Belfast, UK.,School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
| |
Collapse
|
4
|
Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2016; 23:672-80. [PMID: 27280619 DOI: 10.1128/cvi.00267-16] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Accepted: 05/31/2016] [Indexed: 11/20/2022]
Abstract
Immunological responses to vaccination can differ depending on whether the vaccine is given alone or with other vaccines. This study was a retrospective evaluation of the immunogenicity of a tetravalent meningococcal conjugate vaccine for serogroups A, C, W, and Y (MenACWY) administered alone (n = 41) or concomitantly with other vaccines (n = 279) to U.S. military personnel (mean age, 21.6 years) entering the military between 2006 and 2008. Concomitant vaccines included tetanus/diphtheria (Td), inactivated polio vaccine (IPV), hepatitis vaccines, and various influenza vaccines, among others; two vaccine groups excluded Tdap and IPV. Immune responses were evaluated in baseline and postvaccination sera for Neisseria meningitidis serogroups C and Y 1 to 12 months (mean, 4.96 months) following vaccination. Functional antibodies were measured by using a serum bactericidal antibody assay with rabbit complement (rSBA) and by measurement of serogroup-specific immunoglobulin G (IgG) antibodies. The percentage of vaccinees reaching threshold levels (IgG concentration in serum, ≥2 μg/ml; rSBA titer, ≥8) corresponding to an immunologic response was higher postvaccination than at baseline (P < 0.001). Administration of MenACWY along with other vaccines was associated with higher geometric means of IgG concentrations and rSBA titers than those measured 4.60 months after a single dose of MenACWY. In addition, higher percentages of vaccinees reached the immunological threshold (range of odds ratios [ORs], 1.5 to 21.7) and more of them seroconverted (OR range, 1.8 to 4.8) when MenACWY was administered with any other vaccine than when administered alone. Additional prospective randomized clinical trials are needed to confirm the observed differences among groups in the immune response to MenACWY when given concomitantly with other vaccines to U.S. military personnel.
Collapse
|